Selenium Yeast Gene Expression Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current selenium treatments for neurodegenerative diseases lack specificity in targeting gene expression associated with disease and aging, with varying forms of selenium exhibiting different absorption and toxicity profiles, necessitating the identification of effective forms for customized treatments.
Innovation Solution
The use of specific forms of selenium, such as SEL-PLEX, to alter gene expression in the cerebral cortex, specifically reducing the expression of genes like C1q, Cathepsin, presenilin, and nicastrin, which are involved in the processing of amyloid precursor protein, thereby inhibiting the formation of Alzheimer's disease plaques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If inorganic selenium compounds are used for treatment, then cost and availability are improved, but absorption efficiency and toxicity are worsened
Solution Approach 1:
The patent changes the chemical form of selenium from inorganic compounds to organic selenium compounds, specifically identifying selenium yeast as the preferred form. This parameter change in chemical composition resolves the contradiction by improving absorption efficiency while maintaining availability, as organic selenium compounds are better absorbed and utilized by the body compared to inorganic forms.
Solution Approach 2:
The patent employs selenium yeast, which is a composite material containing selenium bound within yeast cell structures. This composite form combines the availability of selenium with improved bioavailability and reduced toxicity, as the yeast matrix facilitates better absorption and utilization of selenium by the body.
2Reliability
If elevated dosage levels of selenium are administered, then therapeutic effect is improved, but toxicity is worsened
Solution Approach 1:
The patent changes the dosage approach by identifying and utilizing organic selenium compounds that provide therapeutic effects at lower, more safe dosage levels. The specific identification of selenium yeast as the preferred form enables effective treatment without requiring elevated doses that cause toxicity, thus resolving the contradiction between therapeutic effect and harmful effects.
Solution Approach 2:
The patent advocates for using selenium yeast at controlled, lower dosage levels rather than relying on high doses of inorganic selenium. This approach treats the therapeutic agent as a controlled-substance model, where moderate, consistent dosing of the organic compound achieves therapeutic effects without the harmful effects associated with high-dose inorganic selenium administration.
3Ease of manufacture
If generic selenium supplementation is used, then ease of manufacture is improved, but specificity for disease-targeted treatment is worsened
Solution Approach 1:
The patent changes the approach from generic selenium supplementation to specific organic selenium compounds, particularly selenium yeast. This parameter change in the type of selenium compound enables disease-targeted treatment by specifically modulating gene expression related to neurodegenerative diseases, while maintaining relative ease of manufacture through established selenium yeast production methods.
Solution Approach 2:
The patent applies local quality by directing selenium supplementation toward specific disease states, particularly neurodegenerative diseases like Alzheimer's. By using organic selenium compounds with specific biological activities, the treatment provides localized therapeutic effect on disease-related gene expression rather than generic supplementation, achieving precision without significantly complicating manufacturing.
Data Source
AI summary
The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX) possess the ability to alter expression of genes associated with disease and/or aging while other forms of selenium (e.g., selenomethionine) do not.